Centene is showing real margin-recovery progress after a difficult 2025, but Medicaid, Marketplace, and Medicare cost pressure still make this a Hold. Q1 2026 results and raised guidance support the turnaround, though the stock already trades near consensus value.
Centene Corp (CNC) is a medium-term recovery story, not a clean compounder. The company produced Q1 2026 adjusted diluted EPS of $3.37, GAAP diluted EPS of $3.11, revenue of $49.9B, and a consolidated health benefits ratio of 87.3%. Management then raised full-year 2026 adjusted EPS guidance to greater than $3.40. Those figures show that the margin-recovery plan is producing results after a difficult 2025.
The counterweight is earnings volatility. CNC reported a $6.7B net loss in 2025, a -3.4% net margin, and a -$13.05 trailing EPS figure. Medicaid medical-cost pressure, Marketplace risk-pool changes, and elevated Medicare utilization remain material factors. The stock's $63.94 reference price sits close to the $65.17 analyst consensus target, which limits the margin of safety for a moderate-risk investor.
The investment case rests on three named facts: Q1 Medicaid HBR improved to 93.1%, Q1 Medicare HBR reached 84.9%, and consolidated adjusted SG&A declined to 7.6% from 7.9% a year earlier. Those gains support a Hold recommendation, with our fair value estimate of $65. The shares become more compelling near $55, while prices above $75 would require stronger evidence that earnings recovery is durable.
Centene is a St. Louis-based managed-care company founded in 1984. It had approximately 61,000 employees and operates across Medicaid, Medicare, Commercial, and Other activities. Its products serve under-insured families, government-sponsored populations, Marketplace customers, and commercial organizations in the United States.
Medicaid is the economic anchor. The 2025 segment data lists $147.6B of Medicaid revenue, equal to 75.8% of total revenue, compared with $42.0B of Commercial revenue and $5.1B of Other revenue. Total 2025 revenue was $194.8B. This mix gives CNC scale, but it also ties the income statement closely to state rate adequacy and Medicaid medical-cost trends.
CNC reported 27.6 million members and $174.6B of 2025 premium and service revenue in company materials. Q1 2026 membership included 12.4 million Medicaid members, 3.58 million Marketplace members, and more than 8.7 million PDP members. The combination of scale and exposure to complex populations creates a sizeable operating platform, but the 2025 loss shows that scale alone does not guarantee stable underwriting.
Medicaid remains the core earnings-repair project. Q1 Medicaid HBR was 93.1%, an improvement of 50 basis points from Q1 2025. Management attributed the quarter to lighter flu activity, a weather-related utilization benefit, and fundamental progress from network optimization, clinical programs, utilization management, and payment-integrity work.
Management's 2026 Medicaid framework assumes a composite rate yield of roughly 4.5% and net medical-cost trend in the mid-4% range. Medicaid membership is expected to decline about 6% from year-end to year-end. That combination means rate adequacy and medical-cost execution matter more than enrollment growth alone.
Medicare delivered a stronger start than planned. Q1 Medicare HBR was 84.9%, with both Medicare Advantage and PDP outperforming expectations. CNC reported approximately 1.0 million Medicare Advantage members at December 31, 2025, and more than 8.7 million PDP members in Q1 2026. Management described Medicare Advantage as moving toward breakeven and expects a path to breakeven financial results in 2027.
Marketplace is the most complicated segment. Ambetter ended Q1 with 3.58 million members, with just under half in Silver plans, roughly 35% in Bronze, and the remainder in Gold. Higher Silver-tier utilization pressured the quarter, but management expects risk-adjustment receipts to offset part of the higher claims cost. Current guidance uses an approximately 3% Marketplace pretax margin, below the original approximately 4% assumption.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CNC's flagship product is its Medicaid managed-care platform. The 12.4 million Q1 members, $147.6B of 2025 segment revenue, and presence across complex categories such as Medicaid expansion, aged, blind, or disabled populations, foster care, behavioral health, and long-term services make this the company's central operating engine.
The product's value proposition is operational rather than cosmetic. CNC manages provider networks, claims, pharmacy oversight, utilization, care coordination, and state reporting for high-need populations. Q1 management cited behavioral health, home health, and high-cost drugs as major trend categories, while also reporting stabilizing year-over-year ABA trends after more than a year of targeted interventions.
The flagship platform is valuable because state contracts are complex and local execution matters. CNC reported contract activity across Nevada, Illinois, California, Iowa, Kansas, Michigan, New Hampshire, and Ohio during 2024 and 2025. Each renewal or award reinforces the operating footprint, but each contract also brings rate and compliance obligations.
CNC's strongest advantage is scale across government-sponsored coverage. The company says it is the largest Medicaid and Marketplace insurer by membership as of December 31, 2025. Its national platform spreads technology, compliance, analytics, and administrative infrastructure across millions of members.
The company is deploying advanced analytics and selective AI-enabled tools in forecasting, medical economics, and payment integrity. Management described these tools as an independent validation layer alongside traditional forecasting, with applications in emerging medical trend, fraud detection, waste reduction, and abnormal claims behavior.
CNC also reported progress in value-based care contracts focused on oncology, chronic kidney disease, and behavioral health. Its Medicare strategy links network design, clinical execution, and total cost of care. These initiatives are strategically sensible because the 2025 loss was tied to medical-cost pressure, but the financial statements do not yet show a stable multi-year margin record.
The dual-eligible opportunity adds another layer. CNC has Medicaid and Medicare infrastructure, while CMS is moving toward greater integration of dual-eligible members through D-SNP structures beginning in 2027, with broader requirements in 2030. That policy direction favors established operators with both platforms.
For a health insurer, the supply chain is the provider network, claims system, pharmacy channel, state agency relationship, and member-service infrastructure. CNC's Q1 operating program included network optimization, utilization management, clinical programs, provider outlier identification, and payment-integrity controls.
Medical claims liability reached $20.6B in Q1 and represented 48 days of claims payable. That figure reflects the scale of the payment engine and gives investors a direct measure of working-capital intensity. Management also expects the faster-completing PDP business to reduce claims-payable days by one or two days as 2026 progresses.
CNC's centralized cash-management structure supports its subsidiaries and channels cash toward debt repayment, capital contributions, share repurchases, acquisitions, and corporate operations. In Q1, the company sold $1.0B of stand-alone 2025 Part D risk-share receivables and used the proceeds to repurchase $1.0B of senior notes.
The addressable market is large and policy-driven. HHS's Office of Inspector General identifies approximately 100 million enrollees across Medicaid and Medicare managed care. Centene's 10-K also cites a Medicare market expected to expand from $1.0T in 2023 to $1.6T by 2030.
Medicare Advantage is already a major channel. CMS projected 35.7 million Medicare Advantage enrollees in 2025, representing approximately 51% of Medicare beneficiaries. That penetration creates a large pool for CNC's Wellcare platform, although risk adjustment, quality ratings, benefit design, and medical utilization determine profitability.
The Marketplace also remains substantial. CMS reported 24.2 million Marketplace plan selections for 2025. CNC's 3.58 million Q1 2026 Marketplace members give it meaningful scale, while the expiration of enhanced premium tax credits changed enrollment and metal-tier behavior in 2026.
The market is fragmented at the state level. KFF reported more than 290 individual Medicaid MCOs under contract with states as of July 2024. Fragmentation creates contract opportunities for large operators, but it also keeps competitive pricing and state procurement pressure firmly in the business model.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
CNC serves several customer groups. Medicaid members include low-income families, children, foster-care populations, aged, blind, or disabled individuals, and people requiring behavioral health or long-term services. Q1 Medicaid membership was 12.4 million.
Medicare customers include seniors and dual-eligible members. Wellcare offers Medicare Advantage plans in 32 states and PDP products in all 50 states. Q1 PDP enrollment exceeded 8.7 million, giving CNC one of the largest stand-alone Part D platforms in the country.
Marketplace customers are more sensitive to subsidy levels, premiums, and plan design. CNC reported that just under half of its Marketplace members were in Silver plans, approximately 35% were in Bronze, and the balance were in Gold. Management also reported that 75% of Silver members were renewals, which supports year-over-year risk-score visibility.
State and federal agencies are also essential customers in an economic sense. Medicaid rates, CMS risk adjustment, Part D risk sharing, and contract requirements directly shape CNC's revenue and margins. The customer relationship is therefore institutional and regulated rather than purely consumer-led.
CNC names UnitedHealth Group (UNH), Elevance Health (ELV), Humana (HUM), and Molina Healthcare (MOH) among its managed-care peers. CVS Health's Aetna is also active across Medicaid, Medicare, and Marketplace products. Regional and nonprofit plans add another layer of competition in state procurement.
UNH reported nearly 7.4 million people in Medicaid-related Community & State programs at December 31, 2025. MOH identifies CNC as a primary competitor for low-income Marketplace membership and lists CNC among its primary Medicaid competitors. These facts confirm that CNC competes against both diversified national insurers and focused Medicaid specialists.
CNC's advantage is breadth. Its 27.6 million members, Medicaid scale, large PDP platform, Marketplace footprint, and dual-eligible positioning give it a broader operating base than a pure-play state Medicaid provider. Its disadvantage is equally clear: more product lines create more exposure to different rate cycles, medical trends, quality rules, and political decisions.
The relevant macro forces for CNC are U.S. health-policy changes, medical inflation, utilization, and interest income rather than overseas geopolitics. Management's 2026 Medicaid outlook assumes a composite rate yield of roughly 4.5% against net trend in the mid-4% range. That narrow relationship leaves little room for underwriting error.
The Marketplace risk pool changed after enhanced premium tax credits expired. CNC reported a shift from Silver toward Bronze products across the market and higher acuity among its retained Silver members. The risk-adjustment mechanism is designed to compensate carriers for relative acuity, but the company's 3% current Marketplace pretax-margin assumption shows that management is not treating the offset as automatic.
Medicare policy also carries direct earnings consequences. Management said finalized 2027 Medicare Advantage rates improved versus the advanced notice but remained below observed medical-cost trend. It still sees a path to breakeven in Medicare Advantage for 2027. The CMS Bridge program and Part D risk-model mechanics add further policy sensitivity.
Higher interest income is a modest offset. CNC increased its 2026 investment and other income outlook by $50M, to $1.45B, after the Q1 performance. That benefit helps earnings, but it does not replace medical-cost control as the central driver of equity value.
Centene’s balance sheet earns a B, but the report still flags a $6.7B net loss in 2025 and a -$13.05 trailing EPS figure that keep leverage and earnings quality in focus.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 adjusted EPS of $3.37 on $49.9B of revenue and an 87.3% consolidated HBR show the margin-repair plan is working, even after a -3.4% net margin in 2025.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 adjusted EPS guidance to greater than $3.40, with Medicaid rate yield around 4.5% and Marketplace pretax margin now modeled near 3%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $63.94, the shares sit close to the $65 fair value estimate and the $65.17 analyst consensus target, leaving limited upside unless recovery proves durable.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The stock looks more attractive near $55, while prices above $75 would need stronger evidence that Medicaid, Medicare, and Marketplace earnings are sustainably improving.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Centene has moved from crisis management toward measurable recovery. Q1 2026 brought $49.9B of revenue, $3.37 of adjusted EPS, $3.4B of free cash flow, a 93.1% Medicaid HBR, and an 84.9% Medicare HBR. Debt-to-capital also fell to 43.2% after a $1.0B note repurchase.
The unfinished work is visible in the 2025 $6.7B net loss, negative trailing EPS, 0.88 debt-to-equity ratio, and Marketplace margin reset to approximately 3%. CNC's scale, state-contract footprint, cash generation, and dual-eligible positioning give the company credible recovery assets. The stock's current price near the $65 fair value estimate already reflects part of that progress.
A Hold is the disciplined position for a moderate-risk, medium-term investor. Stronger Medicaid margins, stable Marketplace risk adjustment, and progress toward Medicare breakeven would improve the case for a higher valuation. Until those gains become consistent across more than one quarter, patience remains more valuable than enthusiasm.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Centene just delivered a strong Q1 2026 beat-and-raise, with improving Medicaid and Medicare margins supporting a recovery thesis. The stock still looks inexpensive versus its earnings power, but execution on medical cost trend remains the key risk.
Centene Corporation (CNC) climbs after a strong Q1 2026 earnings report lifted sentiment. The company raised full-year profit guidance, posted better-than-expected revenue and EPS, and showed improving medical cost control, signaling a possible margin recovery after a volatile stretch.
Intuitive Surgical, Inc. (ISRG) drops after investors reassess its post-earnings growth outlook. Despite strong Q2 results, slower procedure growth, tariff pressure, and a premium valuation are weighing on the stock.